Drug data last refreshed 10h ago · AI intelligence enriched 6d ago
ZINGO is an intradermal lidocaine hydrochloride monohydrate delivery system approved in 2007 for rapid, needle-free local anesthesia. It delivers lidocaine via a CO2-powered microprojection system to provide topical anesthesia before minor procedures. The product offers a non-needle alternative for patients requiring quick-onset local anesthesia.
Established peak-stage product with minimal competitive pressure; team likely focused on market maintenance and operational efficiency rather than aggressive growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children
ZINGO currently shows zero linked job openings, reflecting its established peak-stage lifecycle with a lean, optimized team structure. Opportunities on this product are best suited for professionals seeking stable, mature-brand management roles rather than high-growth commercialization positions.
Worked on ZINGO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo